Business Wire

ORAL-NICOTINE-COMMISSION

6.12.2022 08:03:40 CET | Business Wire | Press release

Share
Sweden Achieves the Lowest Smoking Rate in Europe and is on Track to Become Officially Smoke-Free - The EU Must Take Note

Swedish authorities officially confirmed that the current level of smoking in Sweden has fallen to 5,6%. This makes Swedes the only European nation close to reaching the smoke-free goal set by the EU 18 years ahead of the 2040 target.

In an event organised by the Oral Nicotine Commission in Stockholm, participants took stock of Sweden’s incredible achievements and leadership in the race to end smoking. It is about to become the first country in the world to be defined as “smoke free”, representing a share of less than 5% of the population smoking.

Sweden’s smoking rates have shot down since the 1980s from 35% down to below 6% - a feat that is yet to be replicated by any other nation in the world. The next lowest smoking rate in Europe is double that of Sweden’s, with the EU average sitting somewhere around 23%, four times higher than in Sweden. The result is the lowest tobacco mortality rate in Europe.

A group of leading public health professionals, consumer advocates and harm reduction experts that met to celebrate the achievement on 30 November 2022 in Stockholm have reaffirmed their call to policymakers around the world to ensure that less harmful alternatives to smoking are available to support smokers to quit.

Commenting at the event, Dr. Delon Human, President of Health Diplomats and organiser of the event in Stockholm said: “If all smokers in the world, some 1.1 billion people, would switch to one of less harmful alternative smoke-free, nicotine-based products, it could prevent disease and save millions of lives worldwide. Sweden has found the fire-escape for smokers. We need to work together to repeat the Swedish experience globally to save lives.”

This incredible success story gave attendees the chance to better understand Sweden’s recipe to success, key to which is its openness to less harmful alternatives to smoking. Snus has been at the forefront of the reduction measures, but in recent years, nicotine pouches and e-cigarettes have become another valuable tool for Swedish smokers aiming to quit.

The progressive, pro harm-reduction Swedish model is clearly distinct from the policies proposed by international organisations in favour of tobacco control. At an EU level, harm reduction advocates have fought hard to have harm reduction recognised in the European Beating Cancer Plan. The WHO still refuses to acknowledge its value, despite the fact that harm reduction is explicitly recognised in the Framework Convention for Tobacco Control.

Commenting at the event, Professor Karl Fagerström said: “The upcoming Swedish EU presidency is a great opportunity to share their 5% success story to other EU countries. We hope that Sweden will be generous with sharing this know-how internationally.”

Speakers at the conference emphasised the need for sound evidence-based policy interventions in tobacco control. This translates to the broad adoption of tobacco harm reduction policies that support a journey to quitting smoking.

Ensuring that less harmful alternatives to smoking are affordable, accessible and affordable will be paramount to ensure that other countries can replicate Sweden’s success. This event is the start of much needed discussion of this topic.

The Oral Nicotine Commission is a global not-for-profit association that helps build the evidence base and raise awareness of Oral Nicotine among both governments, public health leaders and the public, thus countering negative, unfounded preconceptions and stereotypes. It addresses policy, science, consumer issues and relevant product innovations. Its views are independent of any brand or manufacturer and focuses on the individual and population health needs of adult smokers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221205005671/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye